Orchestra Medical Ventures
Orchestra Medical Ventures, founded in 2000 and based in New Hope, Pennsylvania, is an investment firm focused on the medical technology sector. The firm utilizes a unique strategy that emphasizes collaboration with leading physicians and experienced technical and business professionals to identify and address significant unmet clinical needs. By immersing itself in high-value clinical areas, Orchestra analyzes opportunities for technological innovations aimed at enhancing patient outcomes while reducing costs and complications. The firm not only invests in but also actively develops optimal device solutions tailored to these identified needs. Orchestra Medical Ventures builds on the foundation laid by its predecessor, Accelerated Technologies, Inc., which operated as a medical device accelerator. This approach aims to increase the likelihood of successful investments in medical technology by aligning the interests of physicians, management, and investors throughout the development process.
Motus GI Holdings
Venture Round in 2016
Motus GI is a medical technology company that focuses on improving outcomes in endoscopy and enhancing patient experiences in the diagnosis and management of gastrointestinal conditions. Based in Fort Lauderdale, Florida, and with operations in Israel, the company has developed the Pure-Vu System, a medical device designed to assist in the cleaning of poorly prepared colons during colonoscopy procedures. This device aims to facilitate better visualization and improve the overall effectiveness of the colonoscopy, contributing to the early detection and prevention of colorectal cancer and other gastrointestinal diseases. The Pure-Vu System has received clearance from the U.S. Food and Drug Administration and is also CE marked for use in the European Economic Area.
Mitralign
Venture Round in 2012
Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.